Impact of CYP2D6, CYP3A5, CYP2C19, CYP2A6, SLCO1B1, ABCB1, and ABCG2 gene polymorphisms on the pharmacokinetics of simvastatin and simvastatin acid

Objective The effects of various polymorphisms in cytochrome P450 (CYP) enzyme and transporter genes on the pharmacokinetics (PK) of simvastatin were evaluated in healthy Korean men. Methods Plasma concentration data for simvastatin and simvastatin acid were pooled from four phase I studies comprising 133 participants. The polymorphisms CYP2D6*4, CYP2D6*5, CYP2D6*14, CYP2D6*41, CYP3A5*3, CYP2C19*2, CYP2C19*3, CYP2A6*7, and CYP2A6*9; SLCO1B1 rs4149056, rs2306283, and rs4149015; ABCB1 rs1128503, rs2032582, and rs1045642; and ABCG2 rs2231142 were evaluated in each participant. Noncompartmental PK results were compared by genotype. Results CYP2D6*5 and CYP2D6*14 were found to be associated with a higher area under the curve (AUC) for simvastatin, whereas the AUC of simvastatin acid was significantly increased in patients with the SLCO1B1 rs4149056, ABCG2 rs2231142, and CYP2D6*41 allele variants. Patients with the CYP2D6*41 variant showed a higher peak serum concentration (Cmax) of both simvastatin and simvastatin acid. The SLCO1B1 rs4149056 and rs4149015 polymorphisms were associated with an increased AUC ratio (i.e. ratio of simvastatin acid to simvastatin), whereas the SLCO1B1 rs4149056 and CYP2D6*5 variants were related to a higher Cmax ratio. Conclusion The CYP2D6*5, CYP2D6*14, CYP2D6*41, CYP3A5*3, SLCO1B1 rs4149056 and rs4149015, and ABCG2 rs2231142 genetic polymorphisms are associated with the PK of both simvastatin and simvastatin acid. This could potentially be used as a basis for individualized simvastatin therapy by predicting the clinical outcomes of this treatment.

[1]  G. Lippi,et al.  Statins for Primary Prevention of Cardiovascular Disease. , 2017, Trends in pharmacological sciences.

[2]  Yusong Chen,et al.  Impact of ABCG2 and SLCO1B1 polymorphisms on pharmacokinetics of rosuvastatin, atorvastatin and simvastatin acid in Caucasian and Asian subjects: a class effect? , 2015, European Journal of Clinical Pharmacology.

[3]  Yusong Chen,et al.  Rosuvastatin pharmacokinetics and pharmacogenetics in Caucasian and Asian subjects residing in the United States , 2015, European Journal of Clinical Pharmacology.

[4]  L Gong,et al.  The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1 and Simvastatin‐Induced Myopathy: 2014 Update , 2014, Clinical pharmacology and therapeutics.

[5]  L. Aarons,et al.  Identification of the Effect of Multiple Polymorphisms on the Pharmacokinetics of Simvastatin and Simvastatin Acid Using a Population‐Modeling Approach , 2014, Clinical pharmacology and therapeutics.

[6]  M. Cosentino,et al.  Association between statin-induced creatine kinase elevation and genetic polymorphisms in SLCO1B1, ABCB1 and ABCG2 , 2014, European Journal of Clinical Pharmacology.

[7]  Sang-Heon Cho,et al.  Population Pharmacokinetic Analysis of Simvastatin and its Active Metabolite with the Characterization of Atypical Complex Absorption Kinetics , 2014, Pharmaceutical Research.

[8]  M. Pirmohamed,et al.  SLCO1B1 Genetic Variant Associated With Statin-Induced Myopathy: A Proof-of-Concept Study Using the Clinical Practice Research Datalink , 2013, Clinical pharmacology and therapeutics.

[9]  R. Hegele,et al.  Clinical and Pharmacogenetic Predictors of Circulating Atorvastatin and Rosuvastatin Concentrations in Routine Clinical Care , 2013, Circulation. Cardiovascular genetics.

[10]  S. Zeng,et al.  Simvastatin pharmacokinetics in healthy Chinese subjects and its relations with CYP2C9, CYP3A5, ABCB1, ABCG2 and SLCO1B1 polymorphisms. , 2013, Die Pharmazie.

[11]  S. Kaul,et al.  Evidence-based use of statins for primary prevention of cardiovascular disease. , 2012, The American journal of medicine.

[12]  B. Tomlinson,et al.  Impact of CYP2D6 polymorphisms on the pharmacokinetics of lovastatin in Chinese subjects , 2012, European Journal of Clinical Pharmacology.

[13]  Wei Zhang,et al.  Use of Transporter Knockdown Caco-2 Cells to Investigate the In Vitro Efflux of Statin Drugs , 2011, Drug Metabolism and Disposition.

[14]  M. Hayden,et al.  Differential effect of the rs4149056 variant in SLCO1B1 on myopathy associated with simvastatin and atorvastatin , 2011, The Pharmacogenomics Journal.

[15]  N. Samani,et al.  Hepatic Metabolism and Transporter Gene Variants Enhance Response to Rosuvastatin in Patients With Acute Myocardial Infarction: The GEOSTAT-1 Study , 2010, Circulation. Cardiovascular genetics.

[16]  B. Tomlinson,et al.  ABCG2 Polymorphism Is Associated With the Low‐Density Lipoprotein Cholesterol Response to Rosuvastatin , 2010, Clinical pharmacology and therapeutics.

[17]  Yiannis S. Chatzizisis,et al.  Risk Factors and Drug Interactions Predisposing to Statin-Induced Myopathy , 2010, Drug safety.

[18]  P. Neuvonen,et al.  Different effects of the ABCG2 c.421C>A SNP on the pharmacokinetics of fluvastatin, pravastatin and simvastatin. , 2009, Pharmacogenomics.

[19]  G. Ginsburg,et al.  The SLCO1B1*5 genetic variant is associated with statin-induced side effects. , 2009, Journal of the American College of Cardiology.

[20]  J. Mega,et al.  Identification of Genetic Variants Associated With Response to Statin Therapy , 2009, Arteriosclerosis, thrombosis, and vascular biology.

[21]  P. Neuvonen,et al.  ABCG2 Polymorphism Markedly Affects the Pharmacokinetics of Atorvastatin and Rosuvastatin , 2009, Clinical pharmacology and therapeutics.

[22]  S. Bates,et al.  ABCG2: a perspective. , 2009, Advanced drug delivery reviews.

[23]  P. Neuvonen,et al.  ABCB1 Haplotypes Differentially Affect the Pharmacokinetics of the Acid and Lactone Forms of Simvastatin and Atorvastatin , 2008, Clinical pharmacology and therapeutics.

[24]  R. Collins,et al.  SLCO1B1 variants and statin-induced myopathy--a genomewide study. , 2008, The New England journal of medicine.

[25]  K. Maeda,et al.  SLCO1B1 (OATP1B1, an Uptake Transporter) and ABCG2 (BCRP, an Efflux Transporter) Variant Alleles and Pharmacokinetics of Pitavastatin in Healthy Volunteers , 2007, Clinical pharmacology and therapeutics.

[26]  L. Tremaine,et al.  P-glycoprotein Has Differential Effects on the Disposition of Statin Acid and Lactone Forms in mdr1a/b Knockout and Wild-Type Mice , 2007, Drug Metabolism and Disposition.

[27]  T. Frudakis,et al.  CYP2D6*4 polymorphism is associated with statin-induced muscle effects , 2007, Pharmacogenetics and genomics.

[28]  C. Sirtori,et al.  Tolerability of statins is not linked to CYP450 polymorphisms, but reduced CYP2D6 metabolism improves cholesteraemic response to simvastatin and fluvastatin. , 2007, Pharmacological research.

[29]  Mikko Niemi,et al.  SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid , 2006, Pharmacogenetics and genomics.

[30]  Ya-li Liu,et al.  Role of BCRP 421C>A polymorphism on rosuvastatin pharmacokinetics in healthy Chinese males. , 2006, Clinica chimica acta; international journal of clinical chemistry.

[31]  M. Eichelbaum,et al.  Impaired expression of CYP2D6 in intermediate metabolizers carrying the *41 allele caused by the intronic SNP 2988G>A: evidence for modulation of splicing events , 2006, Pharmacogenetics and genomics.

[32]  M. Hutz,et al.  The role of common variants of ABCB1, CYP3A4, and CYP3A5 genes in lipid‐lowering efficacy and safety of simvastatin treatment , 2005, Clinical pharmacology and therapeutics.

[33]  Caroline A. Lee,et al.  Rosuvastatin pharmacokinetics and pharmacogenetics in white and Asian subjects residing in the same environment , 2005, Clinical pharmacology and therapeutics.

[34]  H. Masuya,et al.  Statin response and pharmacokinetics variants , 2005, Expert opinion on pharmacotherapy.

[35]  A. V. van Herwaarden,et al.  Sex-Dependent Expression and Activity of the ATP-Binding Cassette Transporter Breast Cancer Resistance Protein (BCRP/ABCG2) in Liver , 2005, Molecular Pharmacology.

[36]  Julia Qiu,et al.  Interactions of Human P-glycoprotein with Simvastatin, Simvastatin Acid, and Atorvastatin , 2004, Pharmaceutical Research.

[37]  T. Strandberg,et al.  Lipid-lowering response to statins is affected by CYP3A5 polymorphism. , 2004, Pharmacogenetics.

[38]  T. Sakaeda,et al.  Metabolic properties of the acid and lactone forms of HMG-CoA reductase inhibitors , 2004, Xenobiotica; the fate of foreign compounds in biological systems.

[39]  B. Ma,et al.  The human hepatic metabolism of simvastatin hydroxy acid is mediated primarily by CYP3A, and not CYP2D6. , 2003, British journal of clinical pharmacology.

[40]  Howard L McLeod,et al.  Pharmacogenomics--drug disposition, drug targets, and side effects. , 2003, The New England journal of medicine.

[41]  B. Ma,et al.  Glucuronidation of statins in animals and humans: a novel mechanism of statin lactonization. , 2002, Drug metabolism and disposition: the biological fate of chemicals.

[42]  Bradford Ld.  CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants. , 2002 .

[43]  M. Haberl,et al.  The genetic determinants of the CYP3A5 polymorphism. , 2001, Pharmacogenetics.

[44]  I. Vermes,et al.  Association of polymorphism in the cytochrome CYP2D6 and the efficacy and tolerability of simvastatin , 2001, Clinical pharmacology and therapeutics.

[45]  M. Mathai,et al.  Simvastatin-diltiazem drug interaction resulting in rhabdomyolysis and hepatitis. , 2001, Tennessee medicine : journal of the Tennessee Medical Association.

[46]  Z. Ouyang,et al.  Direct-injection LC-MS-MS method for high-throughput simultaneous quantitation of simvastatin and simvastatin acid in human plasma. , 2000, Journal of pharmaceutical and biomedical analysis.

[47]  M. Mercuri,et al.  Concomitant use of cytochrome P450 3A4 inhibitors and simvastatin. , 1999, The American journal of cardiology.

[48]  R. Tyndale,et al.  Comparison of three CYP2D6 probe substrates and genotype in Ghanaians, Chinese and Caucasians. , 1998, Pharmacogenetics.

[49]  B H Arison,et al.  In vitro metabolism of simvastatin in humans [SBT]identification of metabolizing enzymes and effect of the drug on hepatic P450s. , 1997, Drug metabolism and disposition: the biological fate of chemicals.

[50]  H. Lennernäs,et al.  Pharmacodynamics and Pharmacokinetics of the HMG-CoA Reductase Inhibitors , 1997, Clinical pharmacokinetics.

[51]  Scandinavian Simvastatin Survival Study Group.  Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S) , 1994, The Lancet.

[52]  V. F. Mauro.  Clinical Pharmacokinetics and Practical Applications of Simvastatin , 1993, Clinical pharmacokinetics.

[53]  Kazuya Maeda,et al.  Clinical significance of organic anion transporting polypeptides (OATPs) in drug disposition: their roles in hepatic clearance and intestinal absorption. , 2013, Biopharmaceutics & drug disposition.

[54]  P. Neuvonen,et al.  Global analysis of genetic variation in SLCO1B1. , 2008, Pharmacogenomics.

[55]  Ulrich M. Zanger,et al.  Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry , 2003, Naunyn-Schmiedeberg's Archives of Pharmacology.

[56]  T. Leemann,et al.  In vitro comparative inhibition profiles of major human drug metabolising cytochrome P450 isozymes (CYP2C9, CYP2D6 and CYP3A4) by HMG-CoA reductase inhibitors , 1996, European Journal of Clinical Pharmacology.

[57]  S. Grundy,et al.  HMG-CoA reductase inhibitors for hypercholesterolemia. , 1988, The New England journal of medicine.